Keywords: fda, panel, backs, approval, merck, co, antifungal
US FDA panel backs approval of Merck & Co's antifungal Cancidas
Article | 17 January 2001
The US Food and Drug Administration's antiviral advisory committee hasrecommended approval of Merck & Co's Cancidas (caspofungin acetate), its investigational intravenous ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
